1,25-(OH)(2)-vitamin D-3 and calcipotriol induce IL-10 receptor gene expression in human epidermal cells

被引:76
作者
Michel, G
Gailis, A
JarzebskaDeussen, B
Muschen, A
Mirmohammadsadegh, A
Ruzicka, T
机构
[1] Department of Dermatology, Heinrich-Heine-Univ. of Dusseldorf, D-40225 Düsseldorf
关键词
antipsoriatic drugs; mechanism of action; cytokine receptor;
D O I
10.1007/s000110050042
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Psoriasis is a common hyperproliferative and inflammatory skin disease with a prevalence of 0.5-3%. Lesional skin is characterized by pathological overexpression of proinflammatory cytokines such as IL-8 and its receptor and the decreased presence of negative regulatory control factors like the anti-oncogene p53. The expression of these genes can be modulated in the opposite direction by antipsoriatic drugs. Another possible candidate gene is the receptor for the anti-inflammatory cytokine IL-10 (IL-10R). Recently, vitamin D-3 and its analogues have attracted interest as new therapeutic agents in the treatment of psoriasis. In extension of these findings we studied here the effect of the physiologically active metabolite, 1,25-dihydroxyvitamin D-3 (calcitriol) and its synthetic analogue calcipotriol (MC 903) on the expression of the IL-10R in HaCaT cells by RT-PCR. IL-10 receptor gene expression was effectively induced in the range of 10(-8)-10(-9) M. Upregulation by calcitriol was about 10-fold, by calcipotriol 12-fold. Induction of the receptor for the anti-inflammatory cytokine IL-10 may be involved in the antipsoriatic action of vitamin D derivatives.
引用
收藏
页码:32 / 34
页数:3
相关论文
共 18 条
  • [1] Carlberg C, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 1, APRIL 1996, V1, P10
  • [2] DEMONSTRATION OF 1,25-DIHYDROXYVITAMIN-D3 RECEPTORS IN HUMAN-SKIN BIOPSIES
    FELDMAN, D
    CHEN, T
    HIRST, M
    COLSTON, K
    KARASEK, M
    CONE, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1980, 51 (06) : 1463 - 1465
  • [3] RESPONSE OF PSORIASIS TO A LYMPHOCYTE-SELECTIVE TOXIN (DAB(389)IL-2) SUGGESTS A PRIMARY IMMUNE, BUT NOT KERATINOCYTE, PATHOGENIC BASIS
    GOTTLIEB, SL
    GILLEAUDEAU, P
    JOHNSON, R
    ESTES, L
    WOODWORTH, TG
    GOTTLIEB, AB
    KRUEGER, JG
    [J]. NATURE MEDICINE, 1995, 1 (05) : 442 - 447
  • [4] Kemeny L, 1994, Exp Dermatol, V3, P1, DOI 10.1111/j.1600-0625.1994.tb00259.x
  • [5] THE INTERLEUKIN-8 RECEPTOR - A POTENTIAL TARGET FOR ANTIPSORIATIC THERAPY
    KEMENY, L
    KENDERESSY, AS
    OLASZ, E
    MICHEL, G
    RUZICKA, T
    FARKAS, B
    DOBOZY, A
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 258 (03) : 269 - 272
  • [6] Antioncogene p53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506)
    Michel, G
    Auer, H
    Kemeny, L
    Bocking, A
    Ruzicka, T
    [J]. BIOCHEMICAL PHARMACOLOGY, 1996, 51 (10) : 1315 - 1320
  • [7] MICHEL G, 1995, SKIN PHARMACOL, V8, P215
  • [8] FK506 in the treatment of inflammatory skin disease: Promises and perspectives
    Michel, G
    Kemeny, L
    Homey, B
    Ruzicka, T
    [J]. IMMUNOLOGY TODAY, 1996, 17 (03): : 106 - 108
  • [9] EXPRESSION OF 1,25-DIHYDROXYVITAMIN-D3 RECEPTORS IN NORMAL AND PSORIATIC SKIN
    MILDE, P
    HAUSER, U
    SIMON, T
    MALL, G
    ERNST, V
    HAUSSLER, MR
    FROSCH, P
    RAUTERBERG, EW
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1991, 97 (02) : 230 - 239
  • [10] AN OPEN STUDY OF VITAMIN-D3 TREATMENT IN PSORIASIS-VULGARIS
    MORIMOTO, S
    YOSHIKAWA, K
    KOZUKA, T
    KITANO, Y
    IMANAKA, S
    FUKUO, K
    KOH, E
    KUMAHARA, Y
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1986, 115 (04) : 421 - 429